alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Webster and others *v.*Bowman and others.

*Circuit*Court, *D. Minnesota.*

December 31, 1885.

Pursue Land—Mortgage of Homestead Land Before Patent Issued—When Valid.

A mortgage executed on land entered under the homestead act of congress, before' expiration of the five-years residence thereon required by the statute, is void ; but if, at the time the mortgage was executed, the right to a, patent had been perfected, by a residence on the land for live years, it will be valid.

This is a suit in ejectment. An amended answer is put in, to which a demurrer is filed.

*Samuel Appleton*and *G. B. Palmer,*for plaintiffs.

*Warner, Stevens é Lawrence,*for defendants.

The court (Nelson, J.)

construed the answer to allege that Webster made a homestead entry July 7, 1875, under the United States laws; and on that day gave 1ns promissory note to one Anna North, and executed a mortgage with his wife to secure on the homestead property the payment of the note. North foreclosed the mortgage, and became purchaser. After the expiration of the time for redemption she conveyed the land; so that, by divers mesne conveyances, her claim of title became vested in a corporation under whom defendant Neuner was in possession. That the receipt given Webster by the receiver of the United States land-office was not the final certificate given after a residence of five years and fulfillment of the requirements of the homestead statute. The demurrer was sustained, and the court held: (1) That the promissory note given under the alleged circumstances, and secured by the mortgage, was a debt within the terms of section *4*of the United States homestead act; (2) that the mortgagee was apprised that the land was not liable to the payment of the debt, it being created after Webster had settled upon tho land under the homestead act of congress, and before expiration of *890the fiye-years residence thereon required; (3) that if, at the time the mortgage was executed, the right to a patent was perfected by a residence on the land for five years, the fourth section of the homestead act did not apply.

Leave was given to amend the answer if it could be shown that *in fact*Webster had resided five years on the premises, or become entitled to a patent at the time the debt was created and the mortgage executed.
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2461 Introduced in House (IH)]

<DOC>

116th CONGRESS
  1st Session
                                H. R. 2461

To amend the Internal Revenue Code of 1986 to allow a refundable credit 
           with respect to any stillborn child of a taxpayer.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 1, 2019

  Mr. Phillips (for himself and Mr. Wittman) introduced the following 
      bill; which was referred to the Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to allow a refundable credit 
           with respect to any stillborn child of a taxpayer.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Savannah Hope Stillbirth Child Tax 
Credit Act''.

SEC. 2. STILLBORN CHILD CREDIT.

    (a) In General.--Section 24 of the Internal Revenue Code of 1986 is 
amended by adding at the end the following new subsection:
    ``(i) Refundable Stillborn Child Credit.--
            ``(1) In general.--The aggregate credits allowed to a 
        taxpayer under subpart C (determined after the application of 
        subsection (d)) shall be increased by $2,000 for each birth by 
        the taxpayer of a stillborn child during the taxable year.
            ``(2) Other requirements.--No increase shall be allowed 
        under paragraph (1), unless--
                    ``(A) the stillborn child would have been a 
                qualifying child (as defined in section 152(c)) of the 
                taxpayer for the taxable year but for such stillbirth, 
                and
                    ``(B) the taxpayer includes with the return of tax 
                for the taxable year with respect to the birth a death 
                certificate, a certificate of birth resulting in 
                stillbirth, or such other documentation as the 
                Secretary may prescribe.
            ``(3) Increase not treated as credit allowed under this 
        subpart.--The amount of the credit allowed under this 
        subsection shall not be treated as a credit allowed under this 
        subpart.''.
    (b) Conforming Amendment.--Section 6211(b)(4)(A) of such Code is 
amended by inserting ``24(i),'' after ``24(d),''.
    (c) Effective Date.--The amendment made by this section shall apply 
to taxable years beginning after December 31, 2018.
                                 <all>
```
Exhibit 32(b)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO
SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and in connection with the Quarterly Report on Form 10-Q of Zep Inc. (the
Corporation) for the quarter ended November 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Mark R. Bachmann, the Executive Vice President and Chief Financial Officer of
the Corporation, hereby certifies that to my knowledge:

(1) The Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation.



|                                                    
|----------------------------------------------------
|/s/ Mark R. Bachmann                                
|Mark R. Bachmann                                    
|Executive Vice President and Chief Financial Officer
|January 5, 2011
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Department of the Army

In accordance with section 10(a)(2) of the Federal Advisory Committee ACT (P.L. 92-463) announcement is made of the following Study Group Meeting:

*Name of Study Group:*                         Asymmetric Study Group.                    

*Date of Meeting:*                         13 June 2001.                    

*Time of Meeting*                         0800-1630.                    

*Place of Meeting:*                         Directed Technologies, Inc., 3601 Wilson Boulevard, Suite 650, Arlington, VA 22201, Phone: (703) 243-3383, FAX: (703) 243-2724.                    

*Agenda:*                         The Army Science Board Study Group will conduct a study on “Asymmetric Threats to Land Based Operations (2015-2020)” as a means of examining and addressing innovative ways that asymmetric threats can be used to disrupt land based operations in the future. The 1-day meeting will be closed to the public. This meeting will be closed to the public in accordance with Section 552(c) of Title 5, U.S.C. Appendix 2, subsection 10(d). For further information, please contact Ms. Betty LaFavers, Office by the Assistant Secretary of the Army (Acquisition, Logistics and Technology), (703) 695-1683.                    

Wayne Joyner,

Executive Assistant, Army Science Board.

### 4th Meeting— “Asymmetric Threats to Land Based Operations 2015-2020''

Director Technologies, Inc., 3601 Wilson Boulevard, Suite 650, Arlington, VA 22201, 703 243-3383)—Fax 703 243-2724.

## Agenda

### 13 June 2001

0800 Administrative Matters—Co-Chairs

815 Executive Session (Internal Working Sessions)—All

1000 Break

1015 Executive Session (Continued)—ALL

1230 Lunch & Roundtable Discussion

1300 Executive Session (Continued)—ALL

1500 Break

1515 Executive Session—ALL

1630 Ajourn—ALL

[FR Doc. 01-13533 Filed 5-29-01; 8:45 am]

BILLING CODE 3710-08-M
Exhibit 10.1



AVAX TECHNOLOGIES, INC.

2000 Hamilton Street, Suite 204

Philadelphia, Pennsylvania  19130



October 2, 2007



Mr. Richard P. Rainey

203 North Blakely Street

Dunmore, Pennsylvania 18512



Re:
        Employment Agreement dated as of April 1, 2004, between AVAX Technologies, Inc. and Richard P. Rainey.




Dear Mr. Rainey:



This letter is to confirm the extension of and certain amendments to the above referenced Employment Agreement. Capitalized terms used herein and not otherwise defined have the meanings given them in the Employment Agreement. We have agreed as follows:



1.         The Corporation engages and employs the Executive, and the Executive hereby accepts engagement and employment as the Chief Executive Officer and President of the Corporation. While the Executive has been elected to the Board of Directors of the Corporation, there is no agreement that the Corporation will continue to elect or nominate the Executive to the Board of Directors.



2.          The term of the Agreement is extended from April 1, 2007 through March 31, 2010.



3.          The Base Salary is $350,000 effective April 1, 2007, and will not be less than that amount during the extended term of the Agreement. The Base Salary will be reviewed annually, commencing April 1, 2008.



4.          For purposes of any notice given pursuant to Section 13 of the Agreement, any notice to the Corporation shall be addressed as follows:



If to Corporation:

AVAX Technologies, Inc.

Attention: John Prendergast

2000 Hamilton Street

Suite 204

Philadelphia, Pennsylvania  19130



With a copy to:

Gilmore & Bell, P.C.

Attention: Richard M. Wright, Jr..

2405 Grand Boulevard, Suite 1100

Kansas City, MO 64111



-1-

---

5.          Except as expressly set forth above, the Agreement remains in full force and effect, without further amendment.



Please acknowledge that the foregoing fairly sets forth our understanding with respect to the amendments to your Employment Agreement, by signing the enclosed copy of this letter and returning it to the undersigned. We appreciate your service the past three years and look forward to the next three years of successful development of the AVAX products and technologies.



Sincerely,





/s/ Andrew W. DahlAndrew W. Dahl, Sc.D.,Chairman, Compensation CommitteeBoard of DirectorsAVAX Technologies, Inc.




AGREED AND ACCEPTED:/s/ Richard P. RaineyRichard P. Rainey

Dated:  October 2, 2007








-2-

---
#### STATE v. SANDERS

No. 330P98

Case below: 130 N.C.App. 343

Petition by defendant for discretionary review pursuant to G.S. 7A-31 denied 30 December 1998.
IN THE SUPREME COURT OF PENNSYLVANIA 

EASTERN DISTRICT 

TYRONE GREEN, 

 Petitioner 

 v. 

COURT OF COMMON PLEAS, 

PHILADELPHIA COUNTY; LAWRENCE 

MAHALLY, SUPERINTENDENT SCI 

DALLAS; SETH WILLIAMS, DISTRICT 

ATTORNEY OF PHILA.; KATHLEEN 

KANE, ATTORNEY GENERAL OF 

PENNSYLVANIA, 

 Respondents 

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

No. 64 EM 2016 

ORDER 

PER CURIAM 

AND NOW, this 21st day of June, 2016, the Application for Leave to File Original 

Process is GRANTED, and the Petition for Writ of Mandamus and/or Extraordinary 

Relief is DENIED.
# C_2010022EN.01002801.xml

| 29.1.2010 | EN | Official Journal of the European Union | C 22/28 |
| --- | --- | --- | --- |

29.1.2010

EN

Official Journal of the European Union

C 22/28

---

Summary of Community decisions on marketing authorisations in respect of medicinal products from 1 December 2009 to 31 December 2009

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council
   (1)
  or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council
   (2)
  )

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council

1

or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council

2

)

2010/C 22/05

—   Issuing, maintenance or modification of a national marketing authorisation

Issuing, maintenance or modification of a national marketing authorisation

| Date of the decision | Name(s) of the medicinal product | Holder(s) of the marketing authorisation | Member State concerned | Date of notification |
| --- | --- | --- | --- | --- |
| 16.12.2009 | REVLIMID | Celgene Europe Limited |
| Riverside House |
| Riverside Walk |
| Windsor |
| Berkshire |
| SL4 1NA |
| UNITED KINGDOM |

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorisation

Member State concerned

Date of notification

16.12.2009

REVLIMID

Celgene Europe Limited

Riverside House

Riverside Walk

Windsor

Berkshire

SL4 1NA

UNITED KINGDOM

This Decision is addressed to the Member States

17.12.2009

10.12.2009

Effentora

| Cephalon Europe |
| --- |
| 5 rue Charles Martigny |
| 94700 Maisons-Alfort |
| FRANCE |

Cephalon Europe

5 rue Charles Martigny

94700 Maisons-Alfort

FRANCE

This Decision is addressed to the Member States

11.12.2009

21.12.2009

Revatio

| Pfizer Limited Sandwich |
| --- |
| Kent |
| CT13 9NJ |
| UNITED KINGDOM |

Pfizer Limited Sandwich

Kent

CT13 9NJ

UNITED KINGDOM

This Decision is addressed to the Member States

22.12.2009

---

(1)  OJ L 311, 28.11.2001, p. 67.

1

(2)  OJ L 311, 28.11.2001, p. 1.

2

---
# C_2018341EN.01001104.xml

| 24.9.2018 | EN | Official Journal of the European Union | C 341/11 |
| --- | --- | --- | --- |

24.9.2018

EN

Official Journal of the European Union

C 341/11

---

Order of the President of the Court of 14 June 2018 — European Commission v Grand Duchy of Luxembourg, intervener: French Republic

(Case C-20/18) (1)

(2018/C 341/18)

Language of the case: French

The President of the Court has ordered that the case be removed from the register.

---

(1)  OJ C 104, 19.3.2018.

---
Exhibit 31.1  Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  I, Steven L. White, the Chief Executive Officer and Chief Financial Officer of Liberty Alliance, Inc.(the Company), certify that:  1. I have reviewed this quarterly report on Form 10-Q of the Company;  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  4. As certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and I have:  a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to usby others within those entities, particularly during the period in which this report is being prepared;  b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this report (the Evaluation Date); and  c) presented in this report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;  5. As certifying officer, I have disclosed, based on my most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):  a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and     April 4, 2008/s/ Steven L. WhiteSteven L. WhiteChief Executive OfficerChief Financial Officer        1
**EXHIBIT 32.1**

** **

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**AND PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Quarterly Report of Lingerie Fighting Championships, Inc. (the “Company”) on Form 10-Q/A No. 1 for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Shaun Donnelly, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

 

| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|-----|-----------------------------------------------------------------------------------------------------------------------|

 

| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

 

  

| March 9, 2018 | By: | */s/ Shaun Donnelly*                                                                                                             |  |
|---------------|-----|----------------------------------------------------------------------------------------------------------------------------------|--|
|               |     | Shaun Donnelly

Chief Executive Officer, Chief Financial Officer,

(Principal Executive Officer and Principal Financial Officer) |  |
#### In the Matter of Eddie S. and Another, Infants. Erie County Department of Social Services, Respondent; Emma C., Appellant.

[874 NYS2d 857] —

Appeal from an order of the Family Court, Erie County (Patricia A. Maxwell, J.), entered December 3, 2007 in a proceeding pursuant to Social Services Law § 384-b. The order terminated the parental rights of respondent.

It is hereby ordered that the order so appealed from is unanimously affirmed without costs. Present — Smith, J.P., Fahey, Peradotto, Garni and Gorski, JJ.
Exhibit 31.2



CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT



I, Jerome Posey, certify that:



1.
        I have reviewed this report on Form I 0-QSB of Viper Powersports Inc.




2.
        Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report.




3.
        Based on my knowledge,
the financial statements, and other financial information included in this report. fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report.




4.
        The registrants
other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e) for the registrant and have:




(a)
        Designed such disclosure
controls and procedures. or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;




(b)
        Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and




(c)
        Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and




5.
        The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the registrants board of directors acting as an audit committee:




(a)
        All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and




(b)
        Any fraud, whether or not
material, that involves management or other employees who have a significant role in the registrants internal control over
financial reporting.




Date:
        May 14, 2007




/s/ Jerome PoseyJerome PoseyPrincipal Financial Officer




---
EXHIBIT 32.1

                           Section 1350 Certification

         I, Sheldon R. Rose, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the
Quarterly Report of Premier Nursing Products Corporation on Form 10-QSB
Amendment No. 1 for the period ended August 31, 2007 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934
and that information contained in such Quarterly Report on Form 10-QSB fairly
presents in all material respects the financial condition and results of
operations of Premier Nursing Products Corporation.

October 22, 2007                        By: /s/ Sheldon R. Rose
                                            -------------------
                                            Sheldon R. Rose,
                                            Principal Executive Officer and
                                            Principal Financial Officer

[A signed original of this written statement required by Section 906 has been
provided to Sunwin International Neutraceuticals, Inc. and will be retained by
Premier Nursing Products Corporation and furnished to the United States
Securities and Exchange Commission or its staff upon request.]